Jinwang Ye

Shenzhen, 518055, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Correction: Accumulation of human full-length tau induces degradation of nicotinic acetylcholine receptor α4 via activating calpain-2.

Correction: Accumulation of human full-length tau induces degradation of nicotinic acetylcholine receptor α4 via activating calpain-2.

Journal: Scientific reports

Published: May 19, 2026

HDAC7 acts as an astrocytic mediator of Aβ pathology that directly engages IKK to drive astrocyte neurotoxicity and neurodegeneration in Alzheimer's disease.

HDAC7 acts as an astrocytic mediator of Aβ pathology that directly engages IKK to drive astrocyte neurotoxicity and neurodegeneration in Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: April 03, 2026

Upregulated astrocytic HDAC7 induces depression-like disorders via deacetylating PINK1 and inhibiting mitophagy.

Upregulated astrocytic HDAC7 induces depression-like disorders via deacetylating PINK1 and inhibiting mitophagy.

Journal: Journal of neuroinflammation

Published: September 26, 2025

Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation.

Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation.

Journal: International immunopharmacology

Published: August 21, 2025

Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis.

Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis.

Journal: Molecular neurodegeneration

Published: August 13, 2024

Periphery Biomarkers Predicting Conversion of Type 2 Diabetes to Pre-Alzheimer-Like Cognitive Decline: A Multicenter Follow-Up Study.

Periphery Biomarkers Predicting Conversion of Type 2 Diabetes to Pre-Alzheimer-Like Cognitive Decline: A Multicenter Follow-Up Study.

Journal: Journal of Alzheimer's disease : JAD

Published: July 26, 2024

Quercetagitrin Inhibits Tau Accumulation and Reverses Neuroinflammation and Cognitive Deficits in P301S-Tau Transgenic Mice.

Quercetagitrin Inhibits Tau Accumulation and Reverses Neuroinflammation and Cognitive Deficits in P301S-Tau Transgenic Mice.

Journal: Molecules (Basel, Switzerland)

Published: March 29, 2023

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy.

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy.

Journal: Neural regeneration research

Published: March 06, 2023

HDAC7 Activates IKK/NF-κB Signaling to Regulate Astrocyte-Mediated Inflammation.

HDAC7 Activates IKK/NF-κB Signaling to Regulate Astrocyte-Mediated Inflammation.

Journal: Molecular neurobiology

Published: March 21, 2022

Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients.

Periphery Biomarkers for Objective Diagnosis of Cognitive Decline in Type 2 Diabetes Patients.

Journal: Frontiers in cell and developmental biology

Published: August 03, 2021

Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway.

Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway.

Journal: Clinical and translational medicine

Published: February 04, 2021

A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.

A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.

Journal: Theranostics

Published: November 09, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026